Searched for
MARK MCDADE
Overweight Lupin, target price Rs 2,500: Axis SecuritiesAxis Securities gives an overweight call on Lupin with a target price of Rs 2500. The company reported a net profit of Rs 858.86 crore for ...- Overweight on Lupin, target price Rs 2,600: Axis SecuritiesAxis Securities recommends an overweight call on Lupin with a target price of Rs 2600. Lupin's current price is Rs 2160. New launches in th...
- Buy Lupin, target price Rs 847.5 : ICICI DirectPrice sustaining above 13 day EMA and close above previous intermediatehighs signaling further upward momentum in coming sessions.
- Buy Lupin, target price Rs 860: Shrikant ChouhanBullish momentum has resumed which suggestsbullish continuation to persist in the near term.
- Sun may have better served by boarding global pharma talentInduction of eminent Indian leaders as independent directors lends credibility, but lack of experts from industry is in contrast to local p...
- Lupin appoints Mark D McDade as independent directorMcDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, includ...
- Dr Reddy's Laboratories to buy UCB's Indian arm for Rs 800 croreUCB, listed on Euronext Brussels, has operations in nearly 40 countries with revenues of €3.3 billion (about Rs 22,275 crore) in 2014.
- Dr Reddy’s agrees to buy UCB business in India for Rs 800 croreThe deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement ...
- Subprime impact: Few women in high positions at Wall Street firmsThe replacement of Erin Callan at Lehman and firing of Zoe Cruz from Morgan leave few women in high positions at Wall Street firms. Beat oi...
Load More
